Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu, None, Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 372, pp. 1909- 1919 ,(2015) , 10.1056/NEJMOA1414325

Andreas H. Marx, Eike C. Burandt, Matthias Choschzick, Ronald Simon, Emre Yekebas, Jussuf T. Kaifi, Martina Mirlacher, Djordje Atanackovic, Carsten Bokemeyer, Walter Fiedler, Luigi Terracciano, Guido Sauter, Jakob R. Izbicki, Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers Human Pathology. ,vol. 41, pp. 1577- 1585 ,(2010) , 10.1016/J.HUMPATH.2010.02.018

Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz-Josef Lenz, Richard M Goldberg, Daniel J Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, Dirk Laurent, None, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial The Lancet. ,vol. 381, pp. 303- 312 ,(2013) , 10.1016/S0140-6736(12)61900-X

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii, Naoya Harada, Masako Soma, Hiromi Okamoto, Masataka Oitate, Shingo Arakawa, Takehiro Hirai, Ryo Atsumi, Takashi Nakada, Ichiro Hayakawa, Yuki Abe, Toshinori Agatsuma, DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 Clinical Cancer Research. ,vol. 22, pp. 5097- 5108 ,(2016) , 10.1158/1078-0432.CCR-15-2822

Maria Luque-Cabal, Paula García-Teijido, Yolanda Fernández-Pérez, Luisa Sánchez-Lorenzo, Isabel Palacio-Vázquez, Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Clinical Medicine Insights: Oncology. ,vol. 10, pp. 21- 30 ,(2016) , 10.4137/CMO.S34537

Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate, Hiroyuki Naito, Toshinori Agatsuma, Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity Cancer Science. ,vol. 107, pp. 1039- 1046 ,(2016) , 10.1111/CAS.12966

Eric Van Cutsem, Andrés Cervantes, Rene Adam, Alberto Sobrero, JH Van Krieken, D Aderka, E Aranda Aguilar, Alberto Bardelli, A Benson, G Bodoky, Fortunato Ciardiello, André D'Hoore, E Diaz-Rubio, J-Y Douillard, M Ducreux, Alfredo Falcone, A Grothey, T Gruenberger, Karin Haustermans, V Heinemann, P Hoff, C-H Köhne, R Labianca, P Laurent-Puig, B Ma, T Maughan, K Muro, N Normanno, P Österlund, WJG Oyen, D Papamichael, G Pentheroudakis, P Pfeiffer, TJ Price, C Punt, J Ricke, A Roth, R Salazar, W Scheithauer, HJ Schmoll, J Tabernero, J Taïeb, Sabine Tejpar, H Wasan, T Yoshino, A Zaanan, D Arnold, None, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Annals of Oncology. ,vol. 27, pp. 1386- 1422 ,(2016) , 10.1093/ANNONC/MDW235

A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold, Treatment decisions in metastatic colorectal cancer - beyond first and second line combination therapies Cancer Treatment Reviews. ,vol. 59, pp. 54- 60 ,(2017) , 10.1016/J.CTRV.2017.04.007

Toshihiko Doi, Kohei Shitara, Yoichi Naito, Akihiko Shimomura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Tatsunori Shimoi, Yasutoshi Kuboki, Nobuaki Matsubara, Atsuko Kitano, Takahiro Jikoh, Caleb Lee, Yoshihiko Fujisaki, Yusuke Ogitani, Antoine Yver, Kenji Tamura, Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study The Lancet Oncology. ,vol. 18, pp. 1512- 1522 ,(2017) , 10.1016/S1470-2045(17)30604-6

Jeffrey S. Ross, Marwan Fakih, Siraj M. Ali, Julia A. Elvin, Alexa B. Schrock, James Suh, Jo-Anne Vergilio, Shakti Ramkissoon, Eric Severson, Sugganth Daniel, David Fabrizio, Garrett Frampton, James Sun, Vincent A. Miller, Philip J. Stephens, Laurie M. Gay, Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. ,vol. 124, pp. 1358- 1373 ,(2018) , 10.1002/CNCR.31125